



## Ziopharm Oncology to Participate in Jefferies Cell Therapy Virtual Summit on October 5, 2020

October 1, 2020

BOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- [Ziopharm Oncology](http://www.ziopharm.com), Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the 7<sup>th</sup> Annual Jefferies Cell Therapy Virtual Summit on October 5, 2020 at 12:30 pm ET.

To access the live webcast presentation, or the subsequent archived recording, please visit the "Investors" section of the Ziopharm website at [www.ziopharm.com](http://www.ziopharm.com).

### **About Ziopharm Oncology, Inc.**

Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body's immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharm's pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral *Sleeping Beauty* gene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufactured *Sleeping Beauty*-enabled CD19-specific CAR-T program. The Company has clinical and strategic partnerships with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and others. For more information, please visit [www.ziopharm.com](http://www.ziopharm.com)

### **Investor Relations Contacts:**

Ziopharm Oncology:

Chris Taylor

VP, Investor Relations and Corporate Communications

T: 617.502.1881

E: [ctaylor@ziopharm.com](mailto:ctaylor@ziopharm.com)

LifeSci Advisors:

Mike Moyer

Managing Director

T: 617.308.4306

E: [mmoyer@lifesciadvisors.com](mailto:mmoyer@lifesciadvisors.com)

### **Media Relations Contact:**

LifeSci Communications:

Patrick Bursey

T: 646.876.4932

E: [pbursey@lifescicomms.com](mailto:pbursey@lifescicomms.com)



Source: ZIOPHARM Oncology Inc